Tyrosine-protein kinase SYK
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric（2） Consistent with protein copy count | Chain AAA； UniProt 6–269 | Not recorded | High affinity immunoglobulin epsilon receptor subunit gamma × 1 （P30273） PO4 PHOSPHATE ION × 2 EDO 1,2-ETHANEDIOL × 1 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME | Resolution 2.20 Å R-free 0.255 |
| 2 | Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric（2） Consistent with protein copy count | Chain BBB； UniProt 6–269 | Not recorded | High affinity immunoglobulin epsilon receptor subunit gamma × 1 （P30273） PO4 PHOSPHATE ION × 2 PEG DI(HYDROXYETHYL)ETHER × 1 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME | Resolution 2.20 Å R-free 0.255 |
| 3 | Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric（2） Consistent with protein copy count | Chain CCC； UniProt 6–269 | Not recorded | High affinity immunoglobulin epsilon receptor subunit gamma × 1 （P30273） PO4 PHOSPHATE ION × 2 EDO 1,2-ETHANEDIOL × 2 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME | Resolution 2.20 Å R-free 0.255 |
| 4 | Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric（2） Consistent with protein copy count | Chain DDD； UniProt 6–269 | Not recorded | High affinity immunoglobulin epsilon receptor subunit gamma × 1 （P30273） PO4 PHOSPHATE ION × 3 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME | Resolution 2.20 Å R-free 0.255 |
| 5 | Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric（2） Consistent with protein copy count | Chain EEE； UniProt 6–269 | Not recorded | High affinity immunoglobulin epsilon receptor subunit gamma × 1 （P30273） PEG DI(HYDROXYETHYL)ETHER × 1 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME | Resolution 2.20 Å R-free 0.255 |
| 6 | Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric（2） Consistent with protein copy count | Chain FFF； UniProt 6–269 | Not recorded | High affinity immunoglobulin epsilon receptor subunit gamma × 1 （P30273） | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME | Resolution 2.20 Å R-free 0.255 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 7Q5T | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain G
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
Chain I
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
Chain K
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
Chain C
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
Chain E
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain K
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain G
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 7 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain I
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1A81 CRYSTAL STRUCTURE OF THE TANDEM SH2 DOMAIN OF THE SYK KINASE BOUND TO A DUALLY TYROSINE-PHOSPHORYLATED ITAM Deposited 1998-03-31 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 8 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
9–262（254 aa）
Fragment：TANDEM SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；10% (W/V) PEG800, 10% (V/V) PEG 200, 0.1M TRIS HCL PH 8.5
|
Resolution 3.00 Å R-free 0.317 |
| 1CSY SYK TYROSINE KINASE C-TERMINAL SH2 DOMAIN COMPLEXED WITH A PHOSPHOPEPTIDEFROM THE GAMMA CHAIN OF THE HIGH AFFINITY IMMUNOGLOBIN G RECEPTOR, NMR Deposited 1995-10-03 | Different construct Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
163–265（103 aa）
Fragment：C-TERMINAL SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1CSZ SYK TYROSINE KINASE C-TERMINAL SH2 DOMAIN COMPLEXED WITH A PHOSPHOPEPTIDEFROM THE GAMMA CHAIN OF THE HIGH AFFINITY IMMUNOGLOBIN G RECEPTOR, NMR Deposited 1995-10-03 | Different construct Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
163–265（103 aa）
Fragment：C-TERMINAL SH2 DOMAIN
|
Not recorded | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1XBA Crystal structure of apo syk tyrosine kinase domain Deposited 2004-08-30 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
353–635（283 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；15% peg 3350, 100mM Tris HCl (pH 8.5)
|
Resolution 2.00 Å R-free 0.278 |
| 1XBB Crystal structure of the syk tyrosine kinase domain with Gleevec Deposited 2004-08-30 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
353–635（283 aa）
|
Not recorded | STI 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；15% peg 3350, 100mM Tris HCl (pH 8.5)
|
Resolution 1.57 Å R-free 0.221 |
| 1XBC Crystal structure of the syk tyrosine kinase domain with Staurosporin Deposited 2004-08-30 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
353–635（283 aa）
|
Not recorded | STU STAUROSPORINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；15% peg 3350, 100mM Tris HCl (pH 8.5)
|
Resolution 2.00 Å R-free 0.294 |
| 3BUW Crystal structure of c-Cbl-TKB domain complexed with its binding motif in Syk Deposited 2008-01-03 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
317–329（13 aa）
Fragment：UNP residues 317-329, pTyr-323 phosphopeptide
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.12M ammonium acetate, 18% PEG 3350, pH 6.5, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.45 Å R-free 0.238 |
| 3BUW Crystal structure of c-Cbl-TKB domain complexed with its binding motif in Syk Deposited 2008-01-03 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
317–329（13 aa）
Fragment：UNP residues 317-329, pTyr-323 phosphopeptide
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.12M ammonium acetate, 18% PEG 3350, pH 6.5, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.45 Å R-free 0.238 |
| 3BUW Crystal structure of c-Cbl-TKB domain complexed with its binding motif in Syk Deposited 2008-01-03 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
317–329（13 aa）
Fragment：UNP residues 317-329, pTyr-323 phosphopeptide
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.12M ammonium acetate, 18% PEG 3350, pH 6.5, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.45 Å R-free 0.238 |
| 3BUW Crystal structure of c-Cbl-TKB domain complexed with its binding motif in Syk Deposited 2008-01-03 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
317–329（13 aa）
Fragment：UNP residues 317-329, pTyr-323 phosphopeptide
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.12M ammonium acetate, 18% PEG 3350, pH 6.5, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.45 Å R-free 0.238 |
| 3EMG Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK) Deposited 2008-09-24 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
349–635（287 aa）
Fragment：Kinase domain: Residues 349-635
|
Not recorded | 685 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；10 mg/mL Protein, 15-20% PEG 8000, 100 mM Sodium nitrate, 100 mM HEPES pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.60 Å R-free 0.222 |
| 3FQE Crystal structure of spleen tyrosine kinase complexed with YM193306 Deposited 2009-01-07 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 365-635, Protein kinase domain
|
Not recorded | P5C 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG 4000, 0.2M AMMONIUM SULFATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 2.50 Å R-free 0.253 |
| 3FQH Crystal structure of spleen tyrosine kinase complexed with a 2-substituted 7-azaindole Deposited 2009-01-07 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 365-635, Protein kinase domain
|
Not recorded | 057 N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；25% PEG 4000, 0.2M AMMONIUM SULFATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 2.26 Å R-free 0.259 |
| 3FQH Crystal structure of spleen tyrosine kinase complexed with a 2-substituted 7-azaindole Deposited 2009-01-07 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
356–635（280 aa）
Fragment：UNP residues 365-635, Protein kinase domain
|
Not recorded | 057 N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；25% PEG 4000, 0.2M AMMONIUM SULFATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 2.26 Å R-free 0.259 |
| 3FQS Crystal structure of spleen tyrosine kinase complexed with R406 Deposited 2009-01-07 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 365-635, Protein kinase domain
|
Not recorded | 585 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；24% PEG 4000, 0.2M AMMONIUM SULFATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 2.10 Å R-free 0.253 |
| 3SRV Crystal structure of spleen tyrosine kinase (SYK) in complex with a diaminopyrimidine carboxamide inhibitor Deposited 2011-07-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
360–635（276 aa）
Fragment：KINASE DOMAIN (UNP Residues 360-635)
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | S19 2-{[(3R,4R)-3-aminotetrahydro-2H-pyran-4-yl]amino}-4-[(4-methylphenyl)amino]pyrimidine-5-carboxamide × 1 GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；20% PEG3350, 0.2M Na-K-Phosphate, 0.1M Bis-Tris-Propane pH 6.5, 5mM DTT, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.95 Å R-free 0.241 |
| 3SRV Crystal structure of spleen tyrosine kinase (SYK) in complex with a diaminopyrimidine carboxamide inhibitor Deposited 2011-07-07 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
360–635（276 aa）
Fragment：KINASE DOMAIN (UNP Residues 360-635)
|
Not recorded | S19 2-{[(3R,4R)-3-aminotetrahydro-2H-pyran-4-yl]amino}-4-[(4-methylphenyl)amino]pyrimidine-5-carboxamide × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；20% PEG3350, 0.2M Na-K-Phosphate, 0.1M Bis-Tris-Propane pH 6.5, 5mM DTT, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.95 Å R-free 0.241 |
| 3TUB Crystal structure of SYK kinase domain with 1-(5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-yl)-3-((1R,2S)-2-phenylcyclopropyl)urea Deposited 2011-09-16 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
Fragment：Spleen Tyrosine Kinase
|
Not recorded | FPU 1-{5-[(6,7-dimethoxyquinolin-4-yl)oxy]pyridin-2-yl}-3-[(1R,2S)-2-phenylcyclopropyl]urea × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25% PEG 3350, 0.2M NaCl, 0.1M bis-Tris pH6.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.23 Å R-free 0.232 |
| 3TUC Crystal structure of SYK kinase domain with 1-benzyl-N-(5-(6,7-dimethoxyquinolin-4-yloxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide Deposited 2011-09-16 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
Fragment：Spleen Tyrosine Kinase
|
Not recorded | FPW 1-benzyl-N-{5-[(6,7-dimethoxyquinolin-4-yl)oxy]pyridin-2-yl}-2-oxo-1,2-dihydropyridine-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25% PEG 1500, 0.1M bis-Tris pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.10 Å R-free 0.285 |
| 3TUD Crystal structure of SYK kinase domain with N-(4-methyl-3-(8-methyl-7-oxo-2-(phenylamino)-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)phenyl)-3-(trifluoromethyl)benzamide Deposited 2011-09-16 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
Fragment：Spleen Tyrosine Kinase
|
Not recorded | FPX N-{4-methyl-3-[8-methyl-7-oxo-2-(phenylamino)-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl]phenyl}-3-(trifluoromethyl)benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.6；291 K；30% PEG MME 2000, 0.1M bis-Tris pH 6.6, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.33 Å R-free 0.263 |
| 3VF8 Crystal Structure of Spleen Tyrosine Kinase Syk Catalytic Domain with Pyrazolylbenzimidazole Inhibitor 416 Deposited 2012-01-09 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
Fragment：unp residues 343-635
|
Not recorded | 0JE 3-[5-(5-ethoxy-6-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.7；292 K；20% PEG3350, 0.1 M Na-citrate, 0.175 M K-phosphate, pH 4.7, VAPOR DIFFUSION, temperature 292K
|
Resolution 2.08 Å R-free 0.241 |
| 3VF9 Crystal Structure of Spleen Tyrosine Kinase Syk Catalytic Domain with Thienopyrazolylindole Inhibitor 027 Deposited 2012-01-09 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
Fragment：unp residues 343-635
|
Not recorded | 477 3-{2-[5-(difluoromethyl)-2H-thieno[3,2-c]pyrazol-3-yl]-1H-indol-6-yl}pentan-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.7；292 K；19% PEG3350, 0.1 M Na-citrate, 0.175 M K-phosphate, pH 4.7, VAPOR DIFFUSION, temperature 292K
|
Resolution 2.30 Å R-free 0.267 |
| 4DFL Crystal structure of spleen tyrosine kinase complexed with a sulfonamidopyrazine piperidine inhibitor Deposited 2012-01-24 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
363–635（273 aa）
|
Not recorded | 0K0 3-amino-6-{3-[(methylsulfonyl)amino]phenyl}-N-(piperidin-4-ylmethyl)pyrazine-2-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1 SO4 SULFATE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.98 Å R-free 0.243 |
| 4DFN Crystal structure of spleen tyrosine kinase complexed with an adamantylpyrazine inhibitor Deposited 2012-01-24 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
363–635（273 aa）
|
Not recorded | 0K1 3-amino-6-[3-(1-methyl-1H-pyrazol-4-yl)phenyl]-N-[(1R,2r,3S,5s,7s)-5-hydroxyadamantan-2-yl]pyrazine-2-carboxamide × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.48 Å R-free 0.273 |
| 4F4P SYK in COMPLEX WITH LIGAND LASW836 Deposited 2012-05-11 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
365–635（271 aa）
|
Not recorded | 0SB N-{6-[3-(piperazin-1-yl)phenyl]pyridin-2-yl}-4-(trifluoromethyl)pyridin-2-amine × 1 SO4 SULFATE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.37 Å R-free 0.285 |
| 4FL1 Structural and Biophysical Characterization of the Syk Activation Switch Deposited 2012-06-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
|
Not recorded | ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.1 M HEPES, 28% PEG 3350, 0.2 M ammonium sulfate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.79 Å R-free 0.225 |
| 4FL2 Structural and Biophysical Characterization of the Syk Activation Switch Deposited 2012-06-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–635（635 aa）
|
Not recorded | MG MAGNESIUM ION × 1 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；12% PEG 3350, 100 mM Hepes, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.19 Å R-free 0.228 |
| 4FL3 Structural and Biophysical Characterization of the Syk Activation Switch Deposited 2012-06-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–635（635 aa）
|
Mutation：Y348F, Y352F | ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；8% PEG 3350, 100 mM Hepes, 200 mM proline, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.208 |
| 4FYN Crystal structure of spleen tyrosine kinase complexed with 3-(8-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-phenylamino}-imidazo[1,2-a]pyrazin-5-yl)-phenol Deposited 2012-07-05 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：RESIDUES 356-635, PROTEIN KINASE DOMAIN
|
Not recorded | 0VE 3-[8-({4-[ethyl(2-hydroxyethyl)amino]phenyl}amino)imidazo[1,2-a]pyrazin-5-yl]phenol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG 4000, 0.2M ammonium sulfate, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 2.32 Å R-free 0.269 |
| 4FYO Crystal structure of spleen tyrosine kinase complexed with N-{(S)-1-[7-(3,4-Dimethoxy-phenylamino)-thiazolo[5,4-d]pyrimidin-5-yl]-pyrrolidin-3-yl}-terephthalamic acid Deposited 2012-07-05 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：RESIDUES 356-635, PROTEIN KINASE DOMAIN
|
Not recorded | 0VF 4-{[(3S)-1-{7-[(3,4-dimethoxyphenyl)amino][1,3]thiazolo[5,4-d]pyrimidin-5-yl}pyrrolidin-3-yl]carbamoyl}benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG 4000, 0.2M ammonium sulfate, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 1.40 Å R-free 0.240 |
| 4FZ6 Crystal structure of spleen tyrosine kinase complexed with [6-((S)-2-Methyl-pyrrolidin-1-yl)-pyridin-2-yl]-(6-phenyl-imidazo[1,2-b]pyridazin-8-yl)-amine Deposited 2012-07-06 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：RESIDUES 356-635, PROTEIN KINASE DOMAIN
|
Not recorded | 0VG N-{6-[(2S)-2-methylpyrrolidin-1-yl]pyridin-2-yl}-6-phenylimidazo[1,2-b]pyridazin-8-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG 4000, 0.2M ammonium sulfate, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 1.85 Å R-free 0.253 |
| 4FZ7 Crystal structure of spleen tyrosine kinase complexed with 6-((1R,2S)-2-Amino-cyclohexylamino)-4-(6-ethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide Deposited 2012-07-06 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：RESIDUES 365-635, PROTEIN KINASE DOMAIN
|
Not recorded | 0VH 6-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(6-ethylpyridin-2-yl)amino]pyridazine-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG 4000, 0.2M ammonium sulfate, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 1.75 Å R-free 0.250 |
| 4GFG Crystal structure of spleen tyrosine kinase complexed with r9021 Deposited 2012-08-03 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：Kinase domain
|
Not recorded | 0XF 6-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(5,6-dimethylpyridin-2-yl)amino]pyridazine-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4；278 K；12% PEG 3350, 0.1M sodium malonate, pH 4.0, VAPOR DIFFUSION, SITTING DROP, temperature 278K
|
Resolution 2.35 Å R-free 0.246 |
| 4I0R Crystal structure of spleen tyrosine kinase complexed with 2-(3,4,5-Trimethoxy-phenyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide Deposited 2012-11-19 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain (UNP residues 356-635)
|
Not recorded | 1B4 N-(propan-2-yl)-2-(3,4,5-trimethoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG4000, 0.2 M ammonium sulfate, 0.1 M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 2.10 Å R-free 0.272 |
| 4I0S Crystal structure of spleen tyrosine kinase complexed with 2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide Deposited 2012-11-19 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain (UNP residues 356-635)
|
Not recorded | 1B5 2-(6-chloro-1-methyl-1H-indazol-3-yl)-N-(propan-2-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG4000, 0.2 M ammonium sulfate, 0.1 M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 1.98 Å R-free 0.236 |
| 4I0T Crystal structure of spleen tyrosine kinase complexed with 2-(5,6,7,8-Tetrahydro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid tert-butylamide Deposited 2012-11-19 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain (UNP residues 356-635)
|
Not recorded | 1B6 N-tert-butyl-2-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；28% PEG4000, 0.2 M ammonium sulfate, 0.1 M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 283K
|
Resolution 1.70 Å R-free 0.268 |
| 4PUZ Crystal structure of spleen tyrosine kinase (Syk) in complex with GS-9973 Deposited 2014-03-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
353–635（283 aa）
Fragment：Syk kinase domain, UNP residues 356-635
|
Not recorded | CG9 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；15% PEG 3350, 100mM Tris pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.08 Å R-free 0.261 |
| 4PUZ Crystal structure of spleen tyrosine kinase (Syk) in complex with GS-9973 Deposited 2014-03-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
353–635（283 aa）
Fragment：Syk kinase domain, UNP residues 356-635
|
Not recorded | CG9 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；15% PEG 3350, 100mM Tris pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.08 Å R-free 0.261 |
| 4PV0 Crystal structure of spleen tyrosine kinase (Syk) in complex with an imidazopyrazine inhibitor Deposited 2014-03-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
363–635（273 aa）
Fragment：Syk kinase domain, UNP residues 363-635
|
Not recorded | CG4 4-[(3-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}benzoyl)amino]benzoic acid × 1 CL CHLORIDE ION × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.00 Å R-free 0.282 |
| 4PX6 SYK catalytic domain in complex with a potent pyridopyrimidinone inhibitor Deposited 2014-03-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：Catalytic Domain
|
Mutation：K467T | 2X6 7-{[(1R,2S)-2-aminocyclohexyl]amino}-5-(1H-indol-7-ylamino)pyrido[4,3-d]pyrimidin-4(3H)-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.2；293 K；20% PEG3350, 0.2M ammonium fluoride, pH 6.2, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.60 Å R-free 0.202 |
| 4RSS Crystal structure of tyrosine-protein kinase SYK with an inhibitor Deposited 2014-11-11 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP RESIDUES 356-635
|
Not recorded | 4MG 1-[(3-methyl-1-{2-[(1,2,3-trimethyl-1H-indol-5-yl)amino]pyrimidin-4-yl}-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；10-20% (v/v) PEG 3350, 100mM Tris-HCl (pH 8.5)
, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.83 Å R-free 0.249 |
| 4RX7 SYK Catalytic Domain Complexed with a Potent Triazine Inhibitor Deposited 2014-12-09 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：Protein kinase domain residues 356-635
|
Not recorded | FMT FORMIC ACID × 1 GOL GLYCEROL × 1 3YV 3-{[(1R,2S)-2-aminocyclohexyl]amino}-5-{[3-(2H-1,2,3-triazol-2-yl)phenyl]amino}-1,2,4-triazine-6-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6；293 K；20% PEG 3350, 0.2M ammonium formate, pH 6.0, vapor diffusion, temperature 293K
|
Resolution 1.80 Å R-free 0.203 |
| 4RX8 SYK Catalytic Domain Complexed with a Potent Triazine Inhibitor2 Deposited 2014-12-09 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：Protein kinase domain residues 356-635
|
Not recorded | GOL GLYCEROL × 2 3YX 3-{[(1R,2S)-2-aminocyclohexyl]amino}-5-(1H-indol-7-ylamino)-1,2,4-triazine-6-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.3；293 K；20% PEG 3350, 0.2M potassium formate, pH 7.3, vapor diffusion, temperature 293K
|
Resolution 1.59 Å R-free 0.207 |
| 4RX9 SYK Catalytic Domain Complexed with a Potent Pyrimidine Inhibitor Deposited 2014-12-09 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
|
Not recorded | GOL GLYCEROL × 1 3YT 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-{[3-(2H-1,2,3-triazol-2-yl)phenyl]amino}pyrimidine-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6；293 K；20% PEG 3350, 0.2M ammonium formate, pH 6.0, vapor diffusion, temperature 293K
|
Resolution 1.75 Å R-free 0.197 |
| 4WNM SYK catalytic domain in complex with a potent triazolopyridine inhibitor Deposited 2014-10-13 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | 3RT N~3~-(tetrahydro-2H-pyran-4-yl)-N~6~-[5-(tetrahydro-2H-pyran-4-ylmethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-1H-indazole-3,6-diamine × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；100 mM MES pH 5.3, 150 mM Ammonium sulfate, and 22% PEG 3350
|
Resolution 2.50 Å R-free 0.260 |
| 4XG2 Crystal structure of ligand-free Syk Deposited 2014-12-30 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.21 Å R-free 0.227 |
| 4XG3 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X3G 4-{[5-fluoro-4-(3-{[(3R)-3-hydroxypyrrolidin-1-yl]methyl}-4-methyl-1H-pyrrol-1-yl)pyrimidin-2-yl]amino}-2,6-dimethylphenyl methanesulfonate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20% (v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.30 Å R-free 0.226 |
| 4XG3 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X3G 4-{[5-fluoro-4-(3-{[(3R)-3-hydroxypyrrolidin-1-yl]methyl}-4-methyl-1H-pyrrol-1-yl)pyrimidin-2-yl]amino}-2,6-dimethylphenyl methanesulfonate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20% (v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.30 Å R-free 0.226 |
| 4XG4 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X4G (3R)-1-{[1-(5-fluoro-2-{[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]amino}pyrimidin-4-yl)-4-methyl-1H-pyrrol-3-yl]methyl}pyrrolidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.30 Å R-free 0.228 |
| 4XG6 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X6G 1-[(1-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-3-methyl-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.40 Å R-free 0.230 |
| 4XG7 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X7G 1-[(3-methyl-1-{2-[(1-methyl-1H-indazol-5-yl)amino]pyrimidin-4-yl}-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 1.76 Å R-free 0.242 |
| 4XG8 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X8G 1-[(1-{2-[(3-chloro-1-methyl-1H-indazol-5-yl)amino]pyrimidin-4-yl}-3-methyl-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.40 Å R-free 0.275 |
| 4XG8 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X8G 1-[(1-{2-[(3-chloro-1-methyl-1H-indazol-5-yl)amino]pyrimidin-4-yl}-3-methyl-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.40 Å R-free 0.275 |
| 4XG9 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X9G 1-[(1-{2-[(3-chloro-1,2-dimethyl-1H-indol-5-yl)amino]pyrimidin-4-yl}-3-methyl-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.91 Å R-free 0.241 |
| 4XG9 Crystal structure of an inhibitor-bound Syk Deposited 2014-12-30 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
356–635（280 aa）
Fragment：protein kinase domain, residues 356-635
|
Not recorded | X9G 1-[(1-{2-[(3-chloro-1,2-dimethyl-1H-indol-5-yl)amino]pyrimidin-4-yl}-3-methyl-1H-pyrazol-4-yl)methyl]azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(v/v) PEG3350, 100 mM Tris-HCl
|
Resolution 2.91 Å R-free 0.241 |
| 4YJO THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222 Deposited 2015-03-03 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Not recorded | 4DF 5-chloro-N~2~-(1,1-dioxido-2,3-dihydro-1,2-benzothiazol-6-yl)-N~4~-ethyl-N~4~-(1H-indazol-4-yl)pyrimidine-2,4-diamine × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM TCEP
|
Resolution 1.60 Å R-free 0.230 |
| 4YJP THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223 Deposited 2015-03-03 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Not recorded | 4DL 2-[{2-[(1,1-dioxido-2,3-dihydro-1,2-benzothiazol-6-yl)amino]pyrimidin-4-yl}(1H-indazol-4-yl)amino]ethanol × 1 DMS DIMETHYL SULFOXIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM TCEP
|
Resolution 1.83 Å R-free 0.258 |
| 4YJQ SYK kinase domain in complex with inhibitor GTC000224 Deposited 2015-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 4DK 3-[1H-indazol-4-yl(2-{[3-(4-methyl-1,3-oxazol-5-yl)phenyl]amino}pyrimidin-4-yl)amino]propan-1-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP
|
Resolution 1.34 Å R-free 0.183 |
| 4YJR SYK kinase domain in complex with inhibitor GTC000225 Deposited 2015-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 4DJ 3-(1H-indazol-4-yl{2-[(1-methyl-1H-indazol-5-yl)amino]pyrimidin-4-yl}amino)propan-1-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP
|
Resolution 1.32 Å R-free 0.180 |
| 4YJS THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226 Deposited 2015-03-03 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Not recorded | 4DN 3-[{2-[(1,1-dioxido-2,3-dihydro-1,2-benzothiazol-6-yl)amino]pyrimidin-4-yl}(1H-indazol-4-yl)amino]propan-1-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；32.5% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM DTT
|
Resolution 2.22 Å R-free 0.226 |
| 4YJT THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233 Deposited 2015-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | GOL GLYCEROL × 1 4DQ N~2~-(1,1-dioxido-2,3-dihydro-1,2-benzothiazol-6-yl)-N~4~-ethyl-5-fluoro-N~4~-(1H-indazol-4-yl)pyrimidine-2,4-diamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP
|
Resolution 1.52 Å R-free 0.208 |
| 4YJU THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249 Deposited 2015-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 4DO N~2~-(1,1-dioxido-2,3-dihydro-1,2-benzothiazol-6-yl)-5-fluoro-N~4~-(1H-indazol-4-yl)-N~4~-methylpyrimidine-2,4-diamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM TCEP
|
Resolution 1.67 Å R-free 0.201 |
| 4YJV THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250 Deposited 2015-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
Fragment：UNP residues 355-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 4DT 3-[6-({4-[ethyl(1H-indazol-4-yl)amino]-5-fluoropyrimidin-2-yl}amino)-2,4-dihydro-1H-indazol-1-yl]propan-1-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP
|
Resolution 1.65 Å R-free 0.222 |
| 5C26 Crystal structure of SYK in complex with compound 1 Deposited 2015-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
343–635（293 aa）
Fragment：UNP residues 343-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 50H 3-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.5；295 K；1.75 M ammonium sulfate, 0.1 M sodium citrate, 0.1 M sodium acetate pH 5.5
|
Resolution 1.95 Å R-free 0.215 |
| 5C27 Crystal structure of SYK in complex with compound 2 Deposited 2015-06-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
343–635（293 aa）
Fragment：UNP residues 343-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 50J 3-{8-[(3,4-dimethoxyphenyl)amino]imidazo[1,2-a]pyrazin-6-yl}-N-[4-(methylcarbamoyl)phenyl]benzamide × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 5.5；298 K；1.75 M ammonium sulfate, 0.1 M sodium citrate, 0.1 M sodium acetate pH 5.5
|
Resolution 2.15 Å R-free 0.225 |
| 5CXH SYK catalytic domain complexed with a potent orally bioavailable thiazole inhibitor Deposited 2015-07-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：Protein kinase domain residues 356-635
|
Mutation：K467T | 55M (4R)-4-[(1R)-1-{[6-(3,4-dimethoxyphenyl)[1,3]thiazolo[5,4-c]pyridin-4-yl]oxy}ethyl]pyrrolidin-2-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.3；277 K；20% PEG3350, 0.2M potassium fluoride, no buffer pH 7.3
|
Resolution 1.90 Å R-free 0.205 |
| 5CXZ SYK catalytic domain complexed with naphthyridine inhibitor Deposited 2015-07-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
|
Mutation：K467T | GOL GLYCEROL × 1 CL CHLORIDE ION × 1 55U N-{7-[4-(dimethylamino)phenyl]-1,6-naphthyridin-5-yl}propane-1,3-diamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 15%, cesium chloride 0.15M
|
Resolution 1.70 Å R-free 0.208 |
| 5CY3 SYK catalytic domain complexed with a potent and orally bioavailable benzisothiazole inhibitor Deposited 2015-07-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：residues 356-635
|
Mutation：K467T | 55Y (5R)-5-[(1R)-1-{[6-(1-methyl-1H-pyrazol-4-yl)-2,1-benzothiazol-4-yl]oxy}ethyl]-1,3-oxazolidin-2-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.1；293 K；PEG 3350 20%, ammonium acetate 0.2M
|
Resolution 1.76 Å R-free 0.195 |
| 5GHV Crystal structure of an inhibitor-bound Syk Deposited 2016-06-20 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
|
Not recorded | X5G 1-({1-[2-({3,5-dimethyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]-4-methyl-1H-pyrrol-3-yl}methyl)azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(V/V) PEG3350, 100 MM TRIS-HCL
|
Resolution 2.80 Å R-free 0.227 |
| 5GHV Crystal structure of an inhibitor-bound Syk Deposited 2016-06-20 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
|
Not recorded | X5G 1-({1-[2-({3,5-dimethyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]-4-methyl-1H-pyrrol-3-yl}methyl)azetidin-3-ol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；278 K；10~20%(V/V) PEG3350, 100 MM TRIS-HCL
|
Resolution 2.80 Å R-free 0.227 |
| 5LMA HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR Deposited 2016-07-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
360–635（276 aa）
Fragment：UNP residues 360-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 6ZG ~{N}'-[7-(4-methylphenyl)pyrido[3,4-b]pyrazin-5-yl]butane-1,4-diamine × 1 GOL GLYCEROL × 2 DMS DIMETHYL SULFOXIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG3350, Sodium formate.
|
Resolution 1.43 Å R-free 0.183 |
| 5LMB HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR Deposited 2016-07-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
360–635（276 aa）
Fragment：UNP residues 360-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 6ZF 7-[6-(dimethylamino)pyridin-3-yl]-~{N}-[[(3~{S})-piperidin-3-yl]methyl]pyrido[3,4-b]pyrazin-5-amine × 1 GOL GLYCEROL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.8；293 K；PEG1500, HEPES, TACSIMATE, GLYCEROL
|
Resolution 1.95 Å R-free 0.228 |
| 5LMB HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR Deposited 2016-07-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
360–635（276 aa）
Fragment：UNP residues 360-635
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 6ZF 7-[6-(dimethylamino)pyridin-3-yl]-~{N}-[[(3~{S})-piperidin-3-yl]methyl]pyrido[3,4-b]pyrazin-5-amine × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.8；293 K；PEG1500, HEPES, TACSIMATE, GLYCEROL
|
Resolution 1.95 Å R-free 0.228 |
| 5T68 Crystal structure of Syk catalytic domain in complex with a furo[3,2-d]pyrimidine Deposited 2016-09-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
Chain B
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 77V N~4~-cyclopropyl-N~2~-(3-methyl-1H-indazol-6-yl)furo[3,2-d]pyrimidine-2,4-diamine × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；14-18% PEG3350, 100 mM Tris pH 8.5 using a seed stock that was grown in PEG 3350 13-20% and 100 mM Tris pH 8.5
|
Resolution 2.93 Å R-free 0.281 |
| 5TIU Crystal structure of SYK kinase domain with inhibitor Deposited 2016-10-03 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 7CU 5-{[(2S)-2-aminopropyl]amino}-3-(1H-indol-2-yl)pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277.15 K；16% PEG3350, 0.1M Tris pH 7.1-7.4
|
Resolution 1.49 Å R-free 0.203 |
| 5TR6 Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK) Deposited 2016-10-25 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 7KG 6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.1；293 K；0.7M Potassium Na Tartrate, 0.06M MES_Na, 0.04M MES
|
Resolution 1.93 Å R-free 0.217 |
| 5TT7 Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK) Deposited 2016-11-01 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 7KF 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.7；293 K；1.2M Potassium Na Tartrate, 0.1M Tris pH 8.7
|
Resolution 1.77 Å R-free 0.234 |
| 5Y5T Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor Deposited 2017-08-09 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 8OR 2-[[(1S,2S)-2-azanylcyclohexyl]amino]-4-[(4-methylsulfonylphenyl)amino]-6H-pyrido[4,3-d]pyrimidin-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；10-20% PEG 3350, 100mM Tris-HCl, pH 8.5
|
Resolution 1.80 Å R-free 0.234 |
| 5Y5U Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor Deposited 2017-08-09 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 8OU 4-[(1-methylindazol-5-yl)amino]-2-(4-oxidanylpiperidin-1-yl)-8H-pyrido[4,3-d]pyrimidin-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；10-20% PEG 3350, 100mM Tris-HCl, pH 8.5
|
Resolution 2.14 Å R-free 0.260 |
| 5Y5U Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor Deposited 2017-08-09 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | 8OU 4-[(1-methylindazol-5-yl)amino]-2-(4-oxidanylpiperidin-1-yl)-8H-pyrido[4,3-d]pyrimidin-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；10-20% PEG 3350, 100mM Tris-HCl, pH 8.5
|
Resolution 2.14 Å R-free 0.260 |
| 6HM6 CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A 2-(PYRIDINYLOXYMETHYL)PYRIDINE INHIBITOR Deposited 2018-09-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
337–612（276 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | GDK 2-(4-methylphenyl)-3-(pyridin-2-ylmethoxy)pyridine × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 1500, HEPES, glycerol, tacsimate.
|
Resolution 2.10 Å R-free 0.290 |
| 6HM7 CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A 2-(PHENOXYMETHYL)PYRIDINE INHIBITOR Deposited 2018-09-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
337–612（276 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | GDH 7-[2-methoxy-6-[(4-methylpyridin-2-yl)methoxy]phenyl]-2,3,4,5-tetrahydro-1~{H}-3-benzazepine × 1 BR BROMIDE ION × 3 GOL GLYCEROL × 1 DMS DIMETHYL SULFOXIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；PEG 3350, bistrispropane, sodium bromide
|
Resolution 1.64 Å R-free 0.210 |
| 6SSB syk in complex with compound 30 Deposited 2019-09-06 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | LUE ~{N}-[4-[5-[(dimethylamino)methyl]-1-methyl-pyrazol-3-yl]pyrimidin-2-yl]-3-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)imidazo[1,5-a]pyridin-7-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.4；293 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 2.08 Å R-free 0.225 |
| 6VOV Crystal structure of Syk in complex with GS-9876 Deposited 2020-01-31 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
363–635（273 aa）
Fragment：UNP Residues 363-635
|
Not recorded | R6D 6-(6-aminopyrazin-2-yl)-N-{4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20% PEG 3350, 100mM Tris pH 8.5
|
Resolution 1.95 Å R-free 0.268 |
| 6VOV Crystal structure of Syk in complex with GS-9876 Deposited 2020-01-31 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
363–635（273 aa）
Fragment：UNP Residues 363-635
|
Not recorded | R6D 6-(6-aminopyrazin-2-yl)-N-{4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20% PEG 3350, 100mM Tris pH 8.5
|
Resolution 1.95 Å R-free 0.268 |
| 6ZC0 SYK Kinase domain in complex with azabenzimidazole inhibitor 2b Deposited 2020-06-09 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QDZ ~{N},~{N}-dimethyl-1-[1-[2-(1-methylindol-4-yl)-3~{H}-imidazo[4,5-b]pyridin-7-yl]pyrazol-4-yl]methanamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.97 Å R-free 0.229 |
| 6ZCP SYK Kinase domain in complex with azabenzimidazole inhibitor 2b Deposited 2020-06-11 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QFK 7-[[4-[4-[(dimethylamino)methyl]pyrazol-1-yl]pyrimidin-2-yl]amino]-~{N},3-dimethyl-imidazo[1,5-a]pyridine-1-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 2.20 Å R-free 0.234 |
| 6ZCQ SYK Kinase domain in complex with diamine inhibitor 5 Deposited 2020-06-11 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QFB 7-[[4-[4-[[(3~{R},4~{R})-3-azanyloxan-4-yl]amino]pyrazol-1-yl]pyrimidin-2-yl]amino]-~{N},3-dimethyl-imidazo[1,5-a]pyridine-1-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 2.32 Å R-free 0.244 |
| 6ZCR SYK Kinase domain in complex with azabenzimidazole inhibitor 7 Deposited 2020-06-12 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | 5JG 6-chloro-2-(2-fluoro-4,5-dimethoxyphenyl)-N-(piperidin-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.73 Å R-free 0.218 |
| 6ZCS SYK Kinase domain in complex with azabenzimidazole inhibitor 3 Deposited 2020-06-12 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QFE (3~{R},4~{R})-~{N}4-[1-[2-(1-methylindol-4-yl)-3~{H}-imidazo[4,5-b]pyridin-7-yl]pyrazol-4-yl]oxane-3,4-diamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.47 Å R-free 0.208 |
| 6ZCU syk in complex with 57262_SYKB-AZ13344324-2 Deposited 2020-06-12 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | 5JG 6-chloro-2-(2-fluoro-4,5-dimethoxyphenyl)-N-(piperidin-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.73 Å R-free 0.218 |
| 6ZCX SYK Kinase domain in complex with azabenzimidazole inhibitor 18 Deposited 2020-06-12 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QFQ ~{N},1-dimethyl-5-[[4-[3-methyl-4-[[(3~{R})-piperidin-3-yl]amino]pyrazol-1-yl]pyrimidin-2-yl]amino]indazole-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.66 Å R-free 0.229 |
| 6ZCY SYK Kinase domain in complex with diamine inhibitor 16 Deposited 2020-06-12 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QF8 ~{N},1-dimethyl-5-[[4-[3-methyl-4-[[(3~{R})-pyrrolidin-3-yl]amino]pyrazol-1-yl]pyrimidin-2-yl]amino]indazole-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；278 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.81 Å R-free 0.223 |
| 7Q5U The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide Deposited 2021-11-04 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain AAA
6–269（264 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 PEG DI(HYDROXYETHYL)ETHER × 1 P4G 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；100 mM MMT buffer, 30% PEG 1000
|
Resolution 2.40 Å R-free 0.259 |
| 7Q5U The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide Deposited 2021-11-04 | Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain BBB
6–269（264 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；100 mM MMT buffer, 30% PEG 1000
|
Resolution 2.40 Å R-free 0.259 |
| 7Q5U The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide Deposited 2021-11-04 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain CCC
6–269（264 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；100 mM MMT buffer, 30% PEG 1000
|
Resolution 2.40 Å R-free 0.259 |
| 7Q5U The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide Deposited 2021-11-04 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain DDD
6–269（264 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；100 mM MMT buffer, 30% PEG 1000
|
Resolution 2.40 Å R-free 0.259 |
| 7Q5U The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide Deposited 2021-11-04 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain EEE
6–269（264 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 1 P4G 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；100 mM MMT buffer, 30% PEG 1000
|
Resolution 2.40 Å R-free 0.259 |
| 7Q5U The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide Deposited 2021-11-04 | Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain FFF
6–269（264 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；100 mM MMT buffer, 30% PEG 1000
|
Resolution 2.40 Å R-free 0.259 |
| 7Q5W The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide Deposited 2021-11-04 | Different ligand/ion Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain AAA
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.266 |
| 7Q5W The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide Deposited 2021-11-04 | Different ligand/ion Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain BBB
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.266 |
| 7Q5W The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide Deposited 2021-11-04 | Different ligand/ion Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain CCC
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.266 |
| 7Q5W The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide Deposited 2021-11-04 | Different ligand/ion Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain DDD
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.266 |
| 7Q5W The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide Deposited 2021-11-04 | Different ligand/ion Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain EEE
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 P4G 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.266 |
| 7Q5W The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide Deposited 2021-11-04 | Different ligand/ion Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain FFF
6–269（264 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME
|
Resolution 2.20 Å R-free 0.266 |
| 7Q63 The tandem SH2 domains of SYK Deposited 2021-11-05 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain AAA
6–269（264 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 1 SCN THIOCYANATE ION × 3 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；200 mM, potassium thiocyanate, 12.5% glycerol, 23% PEG3350
|
Resolution 1.90 Å R-free 0.264 |
| 7Q63 The tandem SH2 domains of SYK Deposited 2021-11-05 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain BBB
6–269（264 aa）
|
Not recorded | SCN THIOCYANATE ION × 4 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；200 mM, potassium thiocyanate, 12.5% glycerol, 23% PEG3350
|
Resolution 1.90 Å R-free 0.264 |
| 7Q63 The tandem SH2 domains of SYK Deposited 2021-11-05 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain CCC
6–269（264 aa）
|
Not recorded | SCN THIOCYANATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；200 mM, potassium thiocyanate, 12.5% glycerol, 23% PEG3350
|
Resolution 1.90 Å R-free 0.264 |
| 7SA7 Crystal structure of the apo SH2 domains of Syk Deposited 2021-09-22 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Protein- 35mg/mL in 10mM HEPES pH 7.0, 50mM NaCl, 5% glycerol and 1mM TCEP
Crystal conditions-0.2M sodium nitrate and 10% w/v PEG 3350
Cryoprotectant-0.2M sodium nitrate, 20% PEG 3350, and 20% glycerol
|
Resolution 3.20 Å R-free 0.304 |
| 7SA7 Crystal structure of the apo SH2 domains of Syk Deposited 2021-09-22 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Protein- 35mg/mL in 10mM HEPES pH 7.0, 50mM NaCl, 5% glycerol and 1mM TCEP
Crystal conditions-0.2M sodium nitrate and 10% w/v PEG 3350
Cryoprotectant-0.2M sodium nitrate, 20% PEG 3350, and 20% glycerol
|
Resolution 3.20 Å R-free 0.304 |
| 7SA7 Crystal structure of the apo SH2 domains of Syk Deposited 2021-09-22 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Protein- 35mg/mL in 10mM HEPES pH 7.0, 50mM NaCl, 5% glycerol and 1mM TCEP
Crystal conditions-0.2M sodium nitrate and 10% w/v PEG 3350
Cryoprotectant-0.2M sodium nitrate, 20% PEG 3350, and 20% glycerol
|
Resolution 3.20 Å R-free 0.304 |
| 7SA7 Crystal structure of the apo SH2 domains of Syk Deposited 2021-09-22 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Protein- 35mg/mL in 10mM HEPES pH 7.0, 50mM NaCl, 5% glycerol and 1mM TCEP
Crystal conditions-0.2M sodium nitrate and 10% w/v PEG 3350
Cryoprotectant-0.2M sodium nitrate, 20% PEG 3350, and 20% glycerol
|
Resolution 3.20 Å R-free 0.304 |
| 7SA7 Crystal structure of the apo SH2 domains of Syk Deposited 2021-09-22 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain E
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Protein- 35mg/mL in 10mM HEPES pH 7.0, 50mM NaCl, 5% glycerol and 1mM TCEP
Crystal conditions-0.2M sodium nitrate and 10% w/v PEG 3350
Cryoprotectant-0.2M sodium nitrate, 20% PEG 3350, and 20% glycerol
|
Resolution 3.20 Å R-free 0.304 |
| 7SA7 Crystal structure of the apo SH2 domains of Syk Deposited 2021-09-22 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 6 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain F
6–269（264 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Protein- 35mg/mL in 10mM HEPES pH 7.0, 50mM NaCl, 5% glycerol and 1mM TCEP
Crystal conditions-0.2M sodium nitrate and 10% w/v PEG 3350
Cryoprotectant-0.2M sodium nitrate, 20% PEG 3350, and 20% glycerol
|
Resolution 3.20 Å R-free 0.304 |
| 8BI2 Syk kinase domain in complex with macrocyclic inhibitor 20a Deposited 2022-11-01 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
343–635（293 aa）
|
Not recorded | QR7 10,13,23-trimethyl-16-oxa-2,4,8,9,13,19,23,30-octazapentacyclo[19.5.2.1^{3,7}.1^{8,11}.0^{24,28}]triaconta-1(27),3,5,7(30),9,11(29),21,24(28),25-nonaen-20-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.4；274 K；0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4
|
Resolution 1.51 Å R-free 0.235 |
| 8RRQ Crystal structure of human SYK in complex with compound 24 Deposited 2024-01-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | A1H2W N-[(1S,2R)-2-azanylcyclohexyl]-5-[2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl]-2-methyl-pyrazole-3-carboxamide × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；277 K；20% PEG 3350, 0.1 M bis tris propane pH 6.5, 0.2 M Na formate
|
Resolution 1.60 Å R-free 0.211 |
| 8RRZ Crystal structure of SYK kinase in complex with compound 1 Deposited 2024-01-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
355–635（281 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | A1H2Y N-[(2S)-1-(azetidin-1-yl)propan-2-yl]-3-{2-[(3,5-dimethoxyphenyl)amino]pyrimidin-4-yl}-1-methyl-1H-pyrazole-5-carboxamide × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；277 K；20% PEG 3350, 0.1 M bis tris propane pH 6.5, 0.2 M Na formate
|
Resolution 1.75 Å R-free 0.214 |
| 8WYW Crystal structure of spleen tyrosine kinase (SYK) in complex with SKI-O-592 (free form of SKI-O-703, cevidoplenib) Deposited 2023-10-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
356–635（280 aa）
Fragment：UNP residues 356-635
Chain B
356–635（280 aa）
Fragment：UNP residues 356-635
|
Not recorded | XFB SKI-O-592 × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；100mM Sodium-HEPES 7.0, 15%(v/v)PEG 4000
|
Resolution 1.90 Å R-free 0.242 |
| 8X5K The Crystal Structure of SYK from Biortus. Deposited 2023-11-17 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
356–635（280 aa）
|
Not recorded | 3YT 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-{[3-(2H-1,2,3-triazol-2-yl)phenyl]amino}pyrimidine-5-carboxamide × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M Li2SO4, 0.1M Bis-Tris pH6.5, 25% PEG 3350
|
Resolution 1.80 Å R-free 0.244 |
| 8XQ0 Crystal structure of spleen tyrosine kinase(SYK)in complex with SKI-G-1653 Deposited 2024-01-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
Chain B
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
Chain C
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
Chain D
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
|
Not recorded | A1LV4 cyclopropyl-[5-[[4-[4-[[(3~{S},4~{S})-3-methoxy-4-oxidanyl-pyrrolidin-1-yl]methyl]-3-methyl-pyrazol-1-yl]pyrimidin-2-yl]amino]-1-methyl-indol-3-yl]methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M HEPES pH 7.0, 10% PEG 6000
|
Resolution 1.95 Å R-free 0.265 |
| 8XQ1 Crystal structure of spleen tyrosine kinase(SYK) in complex with SKI-G-1673 Deposited 2024-01-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
Chain B
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
|
Not recorded | A1LV6 cyclopropyl-[5-[[4-[4-[[(3~{R},4~{S})-3-methoxy-4-oxidanyl-pyrrolidin-1-yl]methyl]-3-methyl-pyrazol-1-yl]pyrimidin-2-yl]amino]-1-methyl-pyrrolo[2,3-b]pyridin-3-yl]methanone × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M Bis-Tris pH 6.5, 20% PEG 1500
|
Resolution 1.50 Å R-free 0.209 |
| 8XQ2 Crystal structure of spleen tyrosine kinase(SYK)in complex with SKI-G-1693 Deposited 2024-01-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
Chain B
356–635（280 aa）
Fragment：PROTEIN KINASE DOMAIN, RESIDUES 356-635
|
Not recorded | GOL GLYCEROL × 1 A1LV7 cyclopropyl-[1-(2-fluoranylethyl)-5-[[4-[4-[[(3~{R},4~{S})-3-methoxy-4-oxidanyl-pyrrolidin-1-yl]methyl]-3-methyl-pyrazol-1-yl]pyrimidin-2-yl]amino]indol-3-yl]methanone × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M tris-HCl pH 8.5, 10% PEG 3350
|
Resolution 1.80 Å R-free 0.238 |
92 other PDB entries and 129 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | KSYK_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain AAA； PDBConstruct 2–265； UniProt 6–269 Author chain BBB； PDBConstruct 2–265； UniProt 6–269 Author chain CCC； PDBConstruct 2–265； UniProt 6–269 Author chain DDD； PDBConstruct 2–265； UniProt 6–269 Author chain EEE； PDBConstruct 2–265； UniProt 6–269 Author chain FFF； PDBConstruct 2–265； UniProt 6–269 |
